For the year ending 2025-12-31, JANX has $1,001,565K in assets. $44,743K in debts. $52,334K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 52,334 | |||
| Short-term investments | 914,233 | |||
| Prepaid expenses and other current assets | 9,320 | |||
| Total current assets | 975,887 | |||
| Restricted cash | 816 | |||
| Total property and equipment | 10,819 | |||
| Less accumulated depreciation | 6,967 | |||
| Property and equipment, net | 3,852 | |||
| Operating lease right-of-use assets | 18,402 | |||
| Other long-term assets | 2,608 | |||
| Total assets | 1,001,565 | |||
| Accounts payable | 4,971 | |||
| Accrued expenses | 17,633 | |||
| Current portion of operating lease liabilities | 2,393 | |||
| Total current liabilities | 24,997 | |||
| Operating lease liabilities, net of current portion | 19,746 | |||
| Total liabilities | 44,743 | |||
| Common stock, 0.001 par value authorized shares - 200,000,000 at december 31, 2025 and 2024, respectively issued shares - 60,384,283 and 59,064,606 at december 31, 2025 and 2024, respectively outstanding shares - 60,384,283 and 59,064,606 at december 31, 2025 and 2024, respectively | 60 | |||
| Additional paid-in capital | 1,303,828 | |||
| Accumulated other comprehensive income | 4,316 | |||
| Accumulated deficit | -351,382 | |||
| Total stockholders' equity | 956,822 | |||
| Total liabilities and stockholders' equity | 1,001,565 | |||
Janux Therapeutics, Inc. (JANX)
Janux Therapeutics, Inc. (JANX)